ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 03/29/2011

ClinicalTrials.gov ID: NCT01005251

Study Identification

Unique Protocol ID:	D9120C00019
Brief Title:	Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
Official Title:	
Secondary IDs:	

Study Status

Record Verification:	March 2011
Overall Status:	Completed
Study Start:	October 2009
Primary Completion:	July 2010 [Actual]
Study Completion:	July 2010 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	
Collaborators:	

Oversight

FDA Regulated?:	Yes
Applicable Trial?:	Section 801 Clinical Trial? Yes

	Delayed Posting? No
IND/IDE Protocol?:	Yes
IND/IDE Information:	Grantor: CDER IND/IDE Number: 78.159 Serial Number: 0042 Has Expanded Access? No
Review Board:	Approval Status: Board Name: Board Affiliation: Phone: Email:
Data Monitoring?:	
Plan to Share Data?:	
Oversight Authorities:	United States: Food and Drug Administration

Study Description

Brief Summary:	This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton Pump Inhibitor (PPI) treatment alone. Another goal of the study is to examine which of the investigated doses of AZD3355 is optimal for treatment of these patients. This study will also measure levels of drug in the blood and see how well it is tolerated.
Detailed Description:	

Conditions

Conditions:	Gastroesophageal Reflux Disease Acid Reflux Heartburn Regurgitation
Keywords:	GERD treatment Acid and non-acid Reflux Heartburn Regurgitation Add-on treatment to PPI

Study Design

Study Type:	Interventional

Primary Purpose:	Treatment
Study Phase:	Phase 2
Intervention Model:	Parallel Assignment
Number of Arms:	5
Masking:	Double Blind (Subject, Investigator)
Allocation:	Randomized
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	661 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: 60 mg PPI+lesogaberan (AZD3355) 60 mg bid	Drug: lesogaberan (AZD3355) 60 mg, oral, capsules, bid for 4 w
Experimental: 120 mg PPI+lesogaberan (AZD3355) 120 mg bid	Drug: lesogaberan (AZD3355) 120 mg, oral, capsules, bid for 4 w
Experimental: 180 mg PPI+lesogaberan (AZD3355) 180 mg bid	Drug: lesogaberan (AZD3355) 180 mg, oral, capsules, bid for 4 w
Experimental: 240 mg PPI+lesogaberan (AZD3355) 240 mg bid	Drug: lesogaberan (AZD3355) 240 mg, oral, capsules, bid for 4 w
Placebo Comparator: Placebo PPI+ Placebo	Drug: Placebo oral,capsules, bid for 4 w

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age:	18 Years
Maximum Age:	70 Years
Gender:	Both
Accepts Healthy Volunteers?:	No
Criteria:	Inclusion Criteria:

- Provision of informed consent prior to any study specific procedures
- Have at least 6 months history of GERD

- Continuously treated during the last 4 weeks before enrolment with daily optimized unchanged PPI therapy for any GERD indication

Exclusion Criteria:

- Patients that have not experienced any GERD symptom improvement at all during PPI treatment
- Prior surgery of the upper gastrointestinal tract.
- Subject who have any of the following conditions or diseases: Heart disease, Angina, Seizure disorders such as epilepsy, Congestive Heart Failure (CHF), Liver disease such as Cirrhosis or Hepatitis, Kidney disease, Lung disease or lung cancer, Cancer

Contacts/Locations

Study Officials: Debra Silberg, MD
Study Director
AstraZeneca

Nicholas Shaheen, MD, MPH
Study Principal Investigator
UNC Hospitals, 4141Chapel Hill, NC 27599 USA

Locations: United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Reporting Groups

	Description
AZD3355 60 mg	PPI+AZD3355 60 mg twice daily (bid)

	Description
AZD3355 120 mg	PPI+AZD3355 120 mg twice daily (bid)
AZD3355 180 mg	PPI+AZD3355 180 mg twice daily (bid)
AZD3355 240 mg	PPI+AZD3355 240 mg twice daily (bid)
Placebo	PPI+Placebo

Overall Study

	AZD3355 60 mg	AZD3355 120 mg	AZD3355 180 mg	AZD3355 240 mg	Placebo
Started	134	125	136	126	140
Completed	121	109	114	114	122
Not Completed	13	16	22	12	18
Withdrawal by Subject	2	5	3	4	9
Eligibility criteria not fulfilled	4	0	4	1	0
Adverse Event	2	6	8	5	4
Protocol Violation	1	0	0	0	2
Developed study-specific withdrawal crit	2	0	3	0	1
Lost to Follow-up	1	4	2	0	0
Physician Decision	0	0	0	0	2
Patient moved	1	0	0	0	0
Wrong drug dispensed	0	1	0	0	0
Randomized in error	0	0	1	1	0
Lack of Efficacy	0	0	1	1	0

Baseline Characteristics

Reporting Groups

	Description
AZD3355 60 mg	PPI+AZD3355 60 mg twice daily (bid)
AZD3355 120 mg	PPI+AZD3355 120 mg twice daily (bid)

	Description
AZD3355 180 mg	PPI+AZD3355 180 mg twice daily (bid)
AZD3355 240 mg	PPI+AZD3355 240 mg twice daily (bid)
Placebo	PPI+Placebo

Baseline Measures

	AZD3355 60 mg	AZD3355 120 mg	AZD3355 180 mg	AZD3355 240 mg	Placebo	Total
Number of Participants	134	125	136	126	140	661
Age, Continuous [units: years] Mean (Standard Deviation)	47.4 (12.3)	46.1 (13.5)	48.0 (12.3)	48.5 (12.1)	48.3 (12.0)	47.7 (12.4)
Gender, Male/Female [units: Participants]						
Female	84	75	75	75	67	376
Male	50	50	61	51	73	285

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Number of Participants With a Change in GERD Symptoms Corresponding to at Least Three More Days of Not More Than Mild Symptoms on Average Per Week During Treatment (Approximately 4 Weeks) Than During Baseline (the 7 Days Before Randomisation)
Measure Description	Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Symptom Questionnaire diary. (GERD = Gastroesophageal Reflux Disease)
Time Frame	The 7 days before randomisation (baseline) and during 26-30 days of treatment
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD3355 60 mg	PPI+AZD3355 60 mg twice daily (bid)

	Description
AZD3355 120 mg	PPI+AZD3355 120 mg twice daily (bid)
AZD3355 180 mg	PPI+AZD3355 180 mg twice daily (bid)
AZD3355 240 mg	PPI+AZD3355 240 mg twice daily (bid)
Placebo	PPI+Placebo

Measured Values

	AZD3355 60 mg	AZD3355 120 mg	AZD3355 180 mg	AZD3355 240 mg	Placebo
Number of Participants Analyzed	134	125	136	126	140
Number of Participants With a Change in GERD Symptoms Corresponding to at Least Three More Days of Not More Than Mild Symptoms on Average Per Week During Treatment (Approximately 4 Weeks) Than During Baseline (the 7 Days Before Randomisation) [units: Participants]	28	32	32	33	25

2. Secondary Outcome Measure:

Measure Title	Absolute Change From Baseline to Treatment Period in Percent Days With at Most Mild GERD Symptoms.
Measure Description	Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Symptom Questionnaire diary (GERD = Gastroesophageal Reflux Disease)
Time Frame	The 7 days before randomisation (baseline) and during 26-30 days of treatment
Safety Issue?	No

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
AZD3355 60 mg	PPI+AZD3355 60 mg twice daily (bid)
AZD3355 120 mg	PPI+AZD3355 120 mg twice daily (bid)

	Description
AZD3355 180 mg	PPI+AZD3355 180 mg twice daily (bid)
AZD3355 240 mg	PPI+AZD3355 240 mg twice daily (bid)
Placebo	PPI+Placebo

Measured Values

	AZD3355 60 mg	AZD3355 120 mg	AZD3355 180 mg	AZD3355 240 mg	Placebo
Number of Participants Analyzed	132	117	133	123	135
Absolute Change From Baseline to Treatment Period in Percent Days With at Most Mild GERD Symptoms. [units: Percent] Median (Inter-Quartile Range)	10.7 (0 to 35.7)	17.2 (0 to 46.4)	11.9 (0 to 40.9)	12.5 (0 to 47.1)	0 (0 to 30.8)

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	As a consequence of the definition of the analysis set for efficacy analysis and safety analysis respectively, one patient was included in the 120 mg group for efficacy analyses and in the 60 mg group for safety analyses.

Reporting Groups

	Description
AZD3355 60 mg	PPI+AZD3355 60 mg twice daily (bid)
AZD3355 120 mg	PPI+AZD3355 120 mg twice daily (bid)
AZD3355 180 mg	PPI+AZD3355 180 mg twice daily (bid)
AZD3355 240 mg	PPI+AZD3355 240 mg twice daily (bid)
Placebo	PPI+Placebo

Serious Adverse Events

	AZD3355 60 mg	AZD3355 120 mg	AZD3355 180 mg	AZD3355 240 mg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	0/	0/	0/	1/	1/
General disorders					
Non-Cardiac Chest Pain [A] †	0/135 (0%)	0/124 (0%)	0/136 (0%)	1/126 (0.79%)	0/140 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)					
Metastatic Gastric Cancer [A] †	0/135 (0%)	0/124 (0%)	0/136 (0%)	0/126 (0%)	1/140 (0.71%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 13.0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	AZD3355 60 mg	AZD3355 120 mg	AZD3355 180 mg	AZD3355 240 mg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	13/	12/	16/	20/	9/
Gastrointestinal disorders					
Diarrhoea [A] †	5/135 (3.7%)	7/124 (5.65%)	6/136 (4.41%)	10/126 (7.94%)	1/140 (0.71%)
Nervous system disorders					
Paraesthesia [A]	8/135 (5.93%)	5/124 (4.03%)	10/136 (7.35%)	11/126 (8.73%)	8/140 (5.71%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 13.0

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

There is an agreement between PI and Sponsor (AZ) or its agents that restricts the PI's right to discuss/publish trial results after the trial is completed.The PI agrees to collaborate in good faith with AZ with regards to content and formation of any publication or disclosure to be made by PI and to pay due consideration to opinions offered by AZ.

Results Point of Contact:

Name/Official Title: Gerard Lynch
Organization: AstraZeneca
Phone:
Email: ClinicalTrialTransparency@astrazeneca.com